A phase II study of neoadjuvant chemoradiotherapy with protons for resectable esophageal cancer

ational Cancer Center0 个研究点目标入组 68 人开始时间: 待定最近更新: 2020年12月2日

试验速览

暂无简介。

•- Good Organ Function
•(1) Absolute neutrophil count > 1500/mm3, platelets =100,000/mm3, Hemoglobin = 9g/dl
•(2) CCr = 20mL/min (Cockroft-Gautl))
•(3) Total billrubin =1.5X UNL, AST /ALT =2.5X UNL
•- FEV1> 1.5L
•- Singed Informed Consesnt

•1. Have a history of esophageal Cancer who previously received topical therapy such as esophageal submucosal resection, surgery, radiation therapy or chemotherapy.
•2. Have a distant metastasis lesion
•3. Have a history of severe hypersenstivity to mannitol, paclitacxel, neoplatin or platinum based durg.
•4. Have a hearing damage.
•5. Have a hemorrhagic tumor
•6. Have a additional malignancy is not disease free for more than 3 years. (except cured basal or smuamous skin cancer, cervial carcinoma in situ)
•7. pregnant or breastfeeding
•8. uncontrolled pychiatric disease, severy head injury, chronic alcoholism or drug addiction. CNS disease.
•9 Have a weight loss of more than 10% during recent 6 months

发起方

ational Cancer Center